))
Comedians Joe Dombrowski (former elementary school teacher) and co-host Gaspare Randazzo (current high school teacher) discuss the chaotic life in and out of the classroom, the nuances of parenting toddlers, and pretty much all things millennial. Each episode is different. Sometimes they'll bring you a Hollywood guest such as comedian Anjelah Reyes-Johnson or renowned School Psychologist Dr.Jody Carrington. Sometimes they might read emails from fans, riffing on their unbelievable, real life, ...
…
continue reading
Your professional development is critical to the care of your patients. Stay on top of the latest treatments and information with ReachMD's CME activities. Our topics span cardiology, diabetes, oncology, women's health and more. And our CME library is continuously growing, every quarter.
…
continue reading
Your professional development is critical to the care of your patients. Stay on top of the latest treatments and information with ReachMD's CME activities. Our topics span cardiology, diabetes, oncology, cardiology, women's health and more. And our CME library is continuously growing, every quarter.
…
continue reading
A podcast on medicine, oncology, & health policy. Host: Vinay Prasad, MD MPH from University of California San Francisco. Tweet your feedback to @Plenary_Session or e-mail plenarysessionpodcast@gmail.com
…
continue reading
Kay Dee Talks is a Tamil podcast started by two friends under the screen name Mr.K and Mr.D. This is a podcast by common men for common people. In Kay Dee Talks we discuss the current happenings in the Tamil society and discuss it critically to provide an alternative view point delivered in Tamil. The podcast is intended to kindle the thoughts of the audiences through engaging conversations. We would let our listeners explore the unheard information from a known fact. We welcome constructive ...
…
continue reading
This is a podcast on latest advances in the understanding and management of blood cancers. Here, we will bring a wide range of experts within hematologic malignancies to discuss various topics in depth. Host: Raj Chakraborty, MD from Columbia University, New York, Ashwin Kishtagari, MD, from Vanderbilt University, Nashville, and Edward Cliff, MD, from Harvard University, Boston Tweet your suggestions and feedback to @rajshekharucms @AshKishtagari @Eddie_Cliff @BloodCancerTalk
…
continue reading
The Blood Podcast summarizes content recently published in Blood, the most cited peer-reviewed publication in the field of hematology.
…
continue reading
Xlibris On Air...get the story behind the story on fiction and literature, thrillers, children's books, mystery and crime novels, romance, science fiction and fantasy, westerns, history, humor, inspiration, and so many more topics. It's all on Xlibris On Air. You'll get to hear the authors talking about their books. Take the opportunity to hear the insights on what inspired them to write it. Join J. Douglas Barker to hear the latest interviews by today's authors!
…
continue reading
CME credits: 1.25 Valid until: 16-08-2025 Claim your CME credit at https://reachmd.com/programs/cme/mrd-testing-to-guide-treatment-considerations-in-cll/26499/ Determining the optimal treatment regimen for patients with chronic lymphocytic leukemia (CLL) has been a clinical challenge, especially since most patients are older than 70 years, present …
…
continue reading
1
Impact of MRD-negative on PFS in myeloma; IPSS-R down-staging before transplant in MDS; hereditary angioedema and venous thromboembolism
21:50
21:50
Play later
Play later
Lists
Like
Liked
21:50
In this week's episode we'll discuss minimal residual disease as an intermediate clinical endpoint for multiple myeloma. Then, we'll learn about IPSS-R downstaging before transplant in MDS. Finally we'll hear about the connection between hereditary angioedema and venous thromboembolism. Featured Articles: EVIDENCE meta-analysis: evaluating minimal …
…
continue reading
1
Protective role of neonatal CMV infection in B-ALL; GVHD targets organoid-forming bile duct stem cells; seven-year outcomes for venetoclax-ibrutinib therapy in MCL
16:56
16:56
Play later
Play later
Lists
Like
Liked
16:56
In this week's episode we'll learn how cytomegalovirus infection early in life depletes preleukemic cells in a mouse model of B-cell acute lymphoblastic leukemia. After that we'll discuss new research, where GVHD targets organoid-forming bile duct stem cells in a TGF-beta-dependent manner. Conversely, a TGF-beta inhibitor protects these stem cells …
…
continue reading
This week, Gaspare goes to the dermatologist and the Zoo while Joe visits the worlds most bizarre grocery store. Indulge in hydration this summer with Liquid I.V. Get 20% off your first order of Liquid I.V. when you go to LIQUID IV DOT COM and use code SOCIAL at checkout. Support the show and get 50% off your first Factor box, plus 20% off your nex…
…
continue reading
Host: Thomas Kipps, MD, PhD Host: William Wierda, MD, PhD Determining the optimal treatment regimen for patients with chronic lymphocytic leukemia (CLL) has been a clinical challenge, especially since most patients are older than 70 years, present with significant coexisting comorbidities, and exhibit one or more common chromosomal alterations. How…
…
continue reading
CME credits: 1.25 Valid until: 16-08-2025 Claim your CME credit at https://reachmd.com/programs/cme/the-challenge-of-bcl-2-resistance-in-cll-treatment-strategies-and-emerging-therapies/26503/ Determining the optimal treatment regimen for patients with chronic lymphocytic leukemia (CLL) has been a clinical challenge, especially since most patients a…
…
continue reading
CME credits: 1.25 Valid until: 16-08-2025 Claim your CME credit at https://reachmd.com/programs/cme/risk-stratification-in-newly-diagnosed-cll/26494/ Determining the optimal treatment regimen for patients with chronic lymphocytic leukemia (CLL) has been a clinical challenge, especially since most patients are older than 70 years, present with signi…
…
continue reading
Host: Talha Munir, PhD Determining the optimal treatment regimen for patients with chronic lymphocytic leukemia (CLL) has been a clinical challenge, especially since most patients are older than 70 years, present with significant coexisting comorbidities, and exhibit one or more common chromosomal alterations. However, outcomes in CLL are improving…
…
continue reading
CME credits: 1.25 Valid until: 16-08-2025 Claim your CME credit at https://reachmd.com/programs/cme/combination-therapy-for-cll-what-evidence-do-we-have/26497/ Determining the optimal treatment regimen for patients with chronic lymphocytic leukemia (CLL) has been a clinical challenge, especially since most patients are older than 70 years, present …
…
continue reading
CME credits: 1.25 Valid until: 16-08-2025 Claim your CME credit at https://reachmd.com/programs/cme/combination-therapy-in-cll-identifying-the-right-patient-for-the-right-treatment-approach/26498/ Determining the optimal treatment regimen for patients with chronic lymphocytic leukemia (CLL) has been a clinical challenge, especially since most patie…
…
continue reading
Host: Thomas Kipps, MD, PhD Determining the optimal treatment regimen for patients with chronic lymphocytic leukemia (CLL) has been a clinical challenge, especially since most patients are older than 70 years, present with significant coexisting comorbidities, and exhibit one or more common chromosomal alterations. However, outcomes in CLL are impr…
…
continue reading
CME credits: 1.25 Valid until: 16-08-2025 Claim your CME credit at https://reachmd.com/programs/cme/frontline-fixed-duration-therapy-in-cll-improving-outcomes-and-tolerability/26495/ Determining the optimal treatment regimen for patients with chronic lymphocytic leukemia (CLL) has been a clinical challenge, especially since most patients are older …
…
continue reading
CME credits: 1.25 Valid until: 16-08-2025 Claim your CME credit at https://reachmd.com/programs/cme/overcoming-disease-progression-in-cll-evidence-based-re-treatment-considerations/26502/ Determining the optimal treatment regimen for patients with chronic lymphocytic leukemia (CLL) has been a clinical challenge, especially since most patients are o…
…
continue reading
Host: Thomas Kipps, MD, PhD Host: William Wierda, MD, PhD Determining the optimal treatment regimen for patients with chronic lymphocytic leukemia (CLL) has been a clinical challenge, especially since most patients are older than 70 years, present with significant coexisting comorbidities, and exhibit one or more common chromosomal alterations. How…
…
continue reading
Host: Thomas Kipps, MD, PhD Host: William Wierda, MD, PhD Determining the optimal treatment regimen for patients with chronic lymphocytic leukemia (CLL) has been a clinical challenge, especially since most patients are older than 70 years, present with significant coexisting comorbidities, and exhibit one or more common chromosomal alterations. How…
…
continue reading
CME credits: 1.25 Valid until: 16-08-2025 Claim your CME credit at https://reachmd.com/programs/cme/fixed-duration-vs-continuous-dosing-approaches-in-cll-impact-on-qol-and-toxicity-risk/26500/ Determining the optimal treatment regimen for patients with chronic lymphocytic leukemia (CLL) has been a clinical challenge, especially since most patients …
…
continue reading
Host: William Wierda, MD, PhD Determining the optimal treatment regimen for patients with chronic lymphocytic leukemia (CLL) has been a clinical challenge, especially since most patients are older than 70 years, present with significant coexisting comorbidities, and exhibit one or more common chromosomal alterations. However, outcomes in CLL are im…
…
continue reading
Host: William Wierda, MD, PhD Determining the optimal treatment regimen for patients with chronic lymphocytic leukemia (CLL) has been a clinical challenge, especially since most patients are older than 70 years, present with significant coexisting comorbidities, and exhibit one or more common chromosomal alterations. However, outcomes in CLL are im…
…
continue reading
CME credits: 1.25 Valid until: 16-08-2025 Claim your CME credit at https://reachmd.com/programs/cme/fixed-duration-therapy-in-the-relapsedrefractory-cll-setting/26501/ Determining the optimal treatment regimen for patients with chronic lymphocytic leukemia (CLL) has been a clinical challenge, especially since most patients are older than 70 years, …
…
continue reading
Host: Thomas Kipps, MD, PhD Determining the optimal treatment regimen for patients with chronic lymphocytic leukemia (CLL) has been a clinical challenge, especially since most patients are older than 70 years, present with significant coexisting comorbidities, and exhibit one or more common chromosomal alterations. However, outcomes in CLL are impr…
…
continue reading
CME credits: 1.25 Valid until: 16-08-2025 Claim your CME credit at https://reachmd.com/programs/cme/mutational-testing-to-guide-therapy-in-cll-why-and-when/26496/ Determining the optimal treatment regimen for patients with chronic lymphocytic leukemia (CLL) has been a clinical challenge, especially since most patients are older than 70 years, prese…
…
continue reading
Host: Thomas Kipps, MD, PhD Host: William Wierda, MD, PhD Determining the optimal treatment regimen for patients with chronic lymphocytic leukemia (CLL) has been a clinical challenge, especially since most patients are older than 70 years, present with significant coexisting comorbidities, and exhibit one or more common chromosomal alterations. How…
…
continue reading
Host: Talha Munir, PhD Determining the optimal treatment regimen for patients with chronic lymphocytic leukemia (CLL) has been a clinical challenge, especially since most patients are older than 70 years, present with significant coexisting comorbidities, and exhibit one or more common chromosomal alterations. However, outcomes in CLL are improving…
…
continue reading
1
Iron, HFE haemochromatosis, and infections; bispecific antibodies improve CAR T-cell response; determinants of outcome in NPM1-mutated AML
23:31
23:31
Play later
Play later
Lists
Like
Liked
23:31
In this week's episode we'll learn about iron, HFE hemochromatosis, and infections. In this large, population-based study, both high and low levels of plasma iron and transferrin saturation were associated with increased risks of infection. Then, we'll discuss how bispecific antibodies improve CAR T-cell response in B-cell malignancies. In-vitro an…
…
continue reading
1
Myeloma Matters: Bispecific Antibody Horizons: Dosing Strategies and Meeting Updates in Myeloma Care
Host: Saad Z. Usmani, MD, MBA, FACP Guest: Joshua Richter, MD Guest: Ashley Steinberger, APP Release date: 8/15/2024 Expiration date: 8/15/2025 Estimated time to complete: 1.0 hour This activity is not accredited for CME/CE credit. This episode of Myeloma Matters reviews the latest data on bispecific antibody therapy for relapsed/refractory multipl…
…
continue reading
1
Episode 49. Updates on Low-Risk MDS with Dr. Maximilian Stahl
43:23
43:23
Play later
Play later
Lists
Like
Liked
43:23
In this episode, we discuss updates on low-risk MDS with Dr. Maximilian Stahl with a focus on imetelstat and luspatercept. Here are the trials we discussed: 1. IWG 2019 response criteria https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7042664/ 2. MEDALIST trial: Luspatercept https://www.nejm.org/doi/10.1056/NEJMoa1908892?url_ver=Z39.88-2003&rfr_id=ori…
…
continue reading
1
HER2-Targeted ADCs in Advanced NSCLC: A Case-Based Approach to Targeted Treatment for Metastatic Disease
CME credits: 0.50 Valid until: 13-08-2025 Claim your CME credit at https://reachmd.com/programs/cme/her2-targeted-adcs-in-advanced-nsclc-a-case-based-approach-to-targeted-treatment-for-metastatic-disease/26285/ The treatment landscape of non-small cell lung cancer (NSCLC) has dramatically changed over the past 20 years. In recent years, the discove…
…
continue reading
1
HER2-Targeted ADCs in Advanced NSCLC: A Case-Based Approach to Targeted Treatment for Metastatic Disease
Host: Justin Gainor, MD Host: Jacob Sands, MD The treatment landscape of non-small cell lung cancer (NSCLC) has dramatically changed over the past 20 years. In recent years, the discovery of targetable molecular alterations and the development of targeted therapies have dramatically changed the treatment outlook for NSCLC. Human epidermal growth fa…
…
continue reading
This week, Gas and Joe get sentimental(ish) as they answer questions from the fans and tell the tale of their friendship. Gaspare takes a family trip and Joe contemplates joining a fantasy football league. Learn more about your ad choices. Visit megaphone.fm/adchoicesBy Joe Dombrowski & Gaspare Randazzo
…
continue reading
1
Case in Point: The Use of GnRH Antagonists Pre- and/or Post-Surgery and the Potential Consequences of Repeat Surgery
CME credits: 0.50 Valid until: 09-08-2025 Claim your CME credit at https://reachmd.com/programs/cme/case-in-point-the-use-of-gnrh-antagonists-pre-andor-post-surgery-and-the-potential-consequences-of-repeat-surgery/24400/ While both medical therapy and surgery often play a role in a woman’s journey with endometriosis, it is less clear how to best se…
…
continue reading
CME credits: 0.50 Valid until: 09-08-2025 Claim your CME credit at https://reachmd.com/programs/cme/creating-a-practice-environment-that-enhances-healthcare-equality-for-all-patients/24397/ Both provider- and patient-related healthcare disparities exist in the diagnosis and management of endometriosis. Many disparities derive from incorrect histori…
…
continue reading
CME credits: 0.25 Valid until: 09-08-2025 Claim your CME credit at https://reachmd.com/programs/cme/patient-centric-tools-to-support-shared-decision-making-diagnosing-and-assessing-endometriosis/24398/ The use of validated patient questionnaires, notably the SF-36 and EHP-30 scales, can greatly hasten the suspicion for an endometriosis diagnosis. C…
…
continue reading
1
Pain Points: Weighing the Benefits and Drawbacks of the GnRH Antagonists Throughout the Endometriosis Treatment Journey
CME credits: 0.50 Valid until: 09-08-2025 Claim your CME credit at https://reachmd.com/programs/cme/pain-points-weighing-the-benefits-and-drawbacks-of-the-gnrh-antagonists-throughout-the-endometriosis-treatment-journey/24399/ GnRH antagonists have emerged as a viable first-line (or subsequent-line) medical therapy for the management of endometriosi…
…
continue reading
1
The Impact of Early Diagnosis in Improving Patient Outcomes in Endometriosis: Physical and Psychosocial Consequences
Host: Lee P. Shulman, MD, FACMG, FACOG Guest: Sawsan As-Sanie, MD Guest: Linda Bradley, MD Endometriosis is often called a public health crisis for women. The delay in diagnosis can be greater than 10 years, during which time women suffer many physical and psychosocial issues that negatively impact their quality of life. Join Drs. Lee Shulman, Saws…
…
continue reading
1
Case in Point: The Use of GnRH Antagonists Pre- and/or Post-Surgery and the Potential Consequences of Repeat Surgery
Host: Lee P. Shulman, MD, FACMG, FACOG Guest: Ayman Al-Hendy, MD, PhD, FRCSC, FACOG, CCRP Guest: James A. Simon, MD, CCD, NCMP, IF, FACOG While both medical therapy and surgery often play a role in a woman’s journey with endometriosis, it is less clear how to best sequence these approaches to optimize a patient’s outcomes. Under what circumstances …
…
continue reading
